-
公开(公告)号:US07544699B2
公开(公告)日:2009-06-09
申请号:US10913168
申请日:2004-08-06
申请人: Adnan M. M. Mjalli , Robert C. Andrews , Xiao-Chuan Guo , Daniel Peter Christen , Devi Reddy Gohimmukkula , Guoxiang Huang , Robert Rothlein , Sameer Tyagi , Tripura Yaramasu , Christopher Behme
发明人: Adnan M. M. Mjalli , Robert C. Andrews , Xiao-Chuan Guo , Daniel Peter Christen , Devi Reddy Gohimmukkula , Guoxiang Huang , Robert Rothlein , Sameer Tyagi , Tripura Yaramasu , Christopher Behme
IPC分类号: C07D217/00 , A61K31/47
CPC分类号: C07D295/155 , C07C233/87 , C07C235/42 , C07C235/52 , C07C235/60 , C07C235/66 , C07C237/36 , C07C237/42 , C07C271/20 , C07C311/08 , C07C311/09 , C07C311/21 , C07C311/44 , C07C317/32 , C07C323/36 , C07C2601/08
摘要: This invention provides aryl and heteroaryl compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention may be antagonists, or partial antagonist of factor IX and/or factor XI and thus, may be useful for inhibiting the intrinsic pathway of blood coagulation. The compounds may be useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway.
摘要翻译: 本发明提供芳基和杂芳基化合物,其制备方法,包含该化合物的药物组合物及其在治疗人或动物病症中的用途。 本发明的化合物可以是拮抗剂或因子IX和/或因子XI的部分拮抗剂,因此可用于抑制凝血的内在途径。 所述化合物可用于各种应用,包括部分由内在凝血途径引起的疾病的管理,治疗和/或控制。
-
2.
公开(公告)号:US07122580B2
公开(公告)日:2006-10-17
申请号:US10637900
申请日:2003-08-08
申请人: Adnan M. M. Mjalli , Robert C. Andrews , Xiao-Chuan Guo , Daniel Peter Christen , Devi Reddy Gohimmukkula , Guoxiang Huang , Robert Rothlein , Sameer Tyagi , Tripura Yaramasu , Christopher Behme
发明人: Adnan M. M. Mjalli , Robert C. Andrews , Xiao-Chuan Guo , Daniel Peter Christen , Devi Reddy Gohimmukkula , Guoxiang Huang , Robert Rothlein , Sameer Tyagi , Tripura Yaramasu , Christopher Behme
IPC分类号: A61K31/245 , C07C233/87
CPC分类号: C07D207/267 , C07C233/29 , C07C233/87 , C07C235/42 , C07C235/52 , C07C235/60 , C07C235/66 , C07C237/36 , C07C237/42 , C07C237/44 , C07C255/60 , C07C257/18 , C07C271/20 , C07C271/44 , C07C311/18 , C07C311/19 , C07C311/44 , C07C317/14 , C07C317/28 , C07C317/36 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2603/74 , C07D207/09 , C07D211/26 , C07D213/30 , C07D213/70 , C07D213/71 , C07D213/74 , C07D213/81 , C07D217/02 , C07D217/16 , C07D217/22 , C07D231/12 , C07D231/14 , C07D231/18 , C07D233/84 , C07D239/94 , C07D249/08 , C07D261/10 , C07D263/32 , C07D271/10 , C07D277/46 , C07D285/08 , C07D295/088 , C07D295/155 , C07D307/66 , C07D307/79 , C07D307/85 , C07D317/60 , C07D333/24 , C07D333/38 , C07D333/70 , C07D401/04 , C07D409/04 , C07D409/06 , C07D413/04
摘要: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as antagonists, or more preferably, partial antagonist of factor IX and thus, may be used to inhibit the intrinsic pathway of blood coagulation. The compounds are useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway utilizing factor IX. Such diseases or disease states include stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures, long periods of confinement, and acquired or inherited pro-coagulant states.
摘要翻译: 本发明提供某些化合物,其制备方法,包含该化合物的药物组合物及其在治疗人或动物疾病中的用途。 本发明的化合物可用作拮抗剂,或更优选为因子IX的部分拮抗剂,因此可用于抑制血液凝固的内在途径。 该化合物可用于各种应用,包括通过利用因子IX的内在凝血途径部分引起的疾病的管理,治疗和/或控制。 这些疾病或疾病状态包括中风,心肌梗死,动脉瘤手术以及与外科手术相关的深部静脉血栓形成,长时间的约束,以及获得性或遗传的促凝血状态。
-
公开(公告)号:US20050059705A1
公开(公告)日:2005-03-17
申请号:US10913168
申请日:2004-08-06
申请人: Adnan Mjalli , Robert Andrews , Xiao-Chuan Guo , Daniel Christen , Devi Gohimmukkula , Guoxiang Huang , Robert Rothlein , Sameer Tyagi , Tripura Yaramasu , Christopher Behme
发明人: Adnan Mjalli , Robert Andrews , Xiao-Chuan Guo , Daniel Christen , Devi Gohimmukkula , Guoxiang Huang , Robert Rothlein , Sameer Tyagi , Tripura Yaramasu , Christopher Behme
IPC分类号: A61P31/12 , C07C233/87 , C07C235/42 , C07C235/52 , C07C235/60 , C07C235/66 , C07C237/36 , C07C237/42 , C07C271/20 , C07C311/08 , C07C311/09 , C07C311/21 , C07C311/44 , C07C317/32 , C07C323/36 , C07D295/155 , C07D41/02 , A61K31/4439 , C07D43/02
CPC分类号: C07D295/155 , C07C233/87 , C07C235/42 , C07C235/52 , C07C235/60 , C07C235/66 , C07C237/36 , C07C237/42 , C07C271/20 , C07C311/08 , C07C311/09 , C07C311/21 , C07C311/44 , C07C317/32 , C07C323/36 , C07C2601/08
摘要: This invention provides aryl and heteroaryl compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention may be antagonists, or partial antagonist of factor IX and/or factor XI and thus, may be useful for inhibiting the intrinsic pathway of blood coagulation. The compounds may be useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway.
摘要翻译: 本发明提供芳基和杂芳基化合物,其制备方法,包含该化合物的药物组合物及其在治疗人或动物病症中的用途。 本发明的化合物可以是拮抗剂或因子IX和/或因子XI的部分拮抗剂,因此可用于抑制凝血的内在途径。 所述化合物可用于各种应用,包括部分由内在凝血途径引起的疾病的管理,治疗和/或控制。
-
公开(公告)号:US20060276518A1
公开(公告)日:2006-12-07
申请号:US11500225
申请日:2006-08-07
申请人: Adnan Mjalli , Robert Andrews , Xiao-Chuan Guo , Daniel Christen , Devi Gohimmukkula , Guoxiang Huang , Robert Rothlein , Sameer Tyagi , Tripura Yaramasu , Christopher Behme
发明人: Adnan Mjalli , Robert Andrews , Xiao-Chuan Guo , Daniel Christen , Devi Gohimmukkula , Guoxiang Huang , Robert Rothlein , Sameer Tyagi , Tripura Yaramasu , Christopher Behme
IPC分类号: A61K31/44 , A61K31/40 , A61K31/18 , A61K31/16 , A61K31/175
CPC分类号: C07D207/267 , C07C233/29 , C07C233/87 , C07C235/42 , C07C235/52 , C07C235/60 , C07C235/66 , C07C237/36 , C07C237/42 , C07C237/44 , C07C255/60 , C07C257/18 , C07C271/20 , C07C271/44 , C07C311/18 , C07C311/19 , C07C311/44 , C07C317/14 , C07C317/28 , C07C317/36 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2603/74 , C07D207/09 , C07D211/26 , C07D213/30 , C07D213/70 , C07D213/71 , C07D213/74 , C07D213/81 , C07D217/02 , C07D217/16 , C07D217/22 , C07D231/12 , C07D231/14 , C07D231/18 , C07D233/84 , C07D239/94 , C07D249/08 , C07D261/10 , C07D263/32 , C07D271/10 , C07D277/46 , C07D285/08 , C07D295/088 , C07D295/155 , C07D307/66 , C07D307/79 , C07D307/85 , C07D317/60 , C07D333/24 , C07D333/38 , C07D333/70 , C07D401/04 , C07D409/04 , C07D409/06 , C07D413/04
摘要: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as antagonists, or more preferably, partial antagonist of factor IX and thus, may be used to inhibit the intrinsic pathway of blood coagulation. The compounds are useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway utilizing factor IX. Such diseases or disease states include stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures, long periods of confinement, and acquired or inherited pro-coagulant states.
-
公开(公告)号:US07906507B2
公开(公告)日:2011-03-15
申请号:US12849225
申请日:2010-08-03
申请人: Adnan M. M. Mjalli , Dharma Rao Polisetti , Thomas Scott Yokum , Kalpathy Santhosh , Mustafa Guzel , Christopher Behme , Stephen Thomas Davis
发明人: Adnan M. M. Mjalli , Dharma Rao Polisetti , Thomas Scott Yokum , Kalpathy Santhosh , Mustafa Guzel , Christopher Behme , Stephen Thomas Davis
IPC分类号: C07D498/02 , A61K31/5365
CPC分类号: C07D498/04 , C07D498/14
摘要: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.
摘要翻译: 本发明提供使用式(I)的恶二唑衍生物及其药学上可接受的盐的方法,其中A,B,C,R,R 1,R 2,R 3,R 4和R 5如本文所述,并且其中所述方法 包括用于治疗和/或预防疾病和疾病如糖尿病的用途。
-
公开(公告)号:US08524708B2
公开(公告)日:2013-09-03
申请号:US12872580
申请日:2010-08-31
申请人: Adnan M. M. Mjalli , Dharma Rao Polisetti , Thomas Scott Yokum , Kalpathy Santhosh , Mustafa Guzel , Christopher Behme , Stephen Thomas Davis
发明人: Adnan M. M. Mjalli , Dharma Rao Polisetti , Thomas Scott Yokum , Kalpathy Santhosh , Mustafa Guzel , Christopher Behme , Stephen Thomas Davis
IPC分类号: C07D498/02 , A61K31/5365
CPC分类号: C07D498/04 , C07D498/14
摘要: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.
摘要翻译: 本发明提供使用式(I)的恶二唑衍生物及其药学上可接受的盐的方法,其中A,B,C,R,R 1,R 2,R 3,R 4和R 5如本文所述,并且其中所述方法 包括用于治疗和/或预防疾病和疾病如糖尿病的用途。
-
7.
公开(公告)号:US08383644B2
公开(公告)日:2013-02-26
申请号:US12825631
申请日:2010-06-29
申请人: Adnan M. M. Mjalli , Christopher Behme , Daniel P. Christen , Devi Reddy Gohimukkula , Dharma Rao Polisetti , James Quada , Jennifer L. R. Freeman , Kalpathy Santhosh , Muralidhar Bondlela , Mustafa Guzel , Ravindra Reddy Yarragunta , Robert Carl Andrews , Stephen Thomas Davis , Thomas Scott Yokum
发明人: Adnan M. M. Mjalli , Christopher Behme , Daniel P. Christen , Devi Reddy Gohimukkula , Dharma Rao Polisetti , James Quada , Jennifer L. R. Freeman , Kalpathy Santhosh , Muralidhar Bondlela , Mustafa Guzel , Ravindra Reddy Yarragunta , Robert Carl Andrews , Stephen Thomas Davis , Thomas Scott Yokum
IPC分类号: C07D491/056 , A61K31/436
CPC分类号: C07D491/056 , C07D319/20 , C07D491/06
摘要: The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.
-
公开(公告)号:US07727983B2
公开(公告)日:2010-06-01
申请号:US12399504
申请日:2009-03-06
申请人: Adnan M. M. Mjalli , Dharma Rao Polisetti , Thomas Scott Yokum , Kalpathy Santhosh , Mustafa Guzel , Christopher Behme , Stephen Thomas Davis
发明人: Adnan M. M. Mjalli , Dharma Rao Polisetti , Thomas Scott Yokum , Kalpathy Santhosh , Mustafa Guzel , Christopher Behme , Stephen Thomas Davis
IPC分类号: C07D498/02 , A61K31/5365
CPC分类号: C07D498/04 , C07D498/14
摘要: The present invention provides oxadiazoanthracene derivatives of the formula (I), wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, pharmaceutical compositions comprising oxadiazoanthracene derivatives, use of the oxadiazoanthracene derivatives for the preparation of pharmaceutical compositions, methods of use thereof for the treatment and/or prevention of disorders and diseases, such as diabetes, and intermediates useful for the preparation of oxadiazoanthracene derivatives of Formula (I).
摘要翻译: 本发明提供式(I)的恶二唑并蒽衍生物,其中A,B,C,R,R 1,R 2,R 3,R 4和R 5如本文所述,包含恶二唑并蒽衍生物的药物组合物,使用恶二唑衍生物用于制备 的药物组合物,其用于治疗和/或预防疾病和疾病的方法,例如糖尿病,以及可用于制备式(I)的恶二唑衍生物的中间体。
-
公开(公告)号:US20100324033A1
公开(公告)日:2010-12-23
申请号:US12872580
申请日:2010-08-31
申请人: Adnan M.M. Mjalli , Dharma Rao Polisetti , Thomas Scott Yokum , Kalpathy Santhosh , Mustafa Guzel , Christopher Behme , Stephen Thomas Davis
发明人: Adnan M.M. Mjalli , Dharma Rao Polisetti , Thomas Scott Yokum , Kalpathy Santhosh , Mustafa Guzel , Christopher Behme , Stephen Thomas Davis
IPC分类号: A61K31/5383 , A61P3/10 , A61P1/12 , A61P3/04
CPC分类号: C07D498/04 , C07D498/14
摘要: The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.
摘要翻译: 本发明提供使用式(I)的恶二唑衍生物及其药学上可接受的盐的方法,其中A,B,C,R,R 1,R 2,R 3,R 4和R 5如本文所述,并且其中所述方法 包括用于治疗和/或预防疾病和疾病如糖尿病的用途。
-
10.
公开(公告)号:US20090306063A1
公开(公告)日:2009-12-10
申请号:US12399504
申请日:2009-03-06
申请人: Adnan M.M. Mjalli , Dharma Rao Polisetti , Thomas Scott Yokum , Kalpathy Santhosh , Mustafa Guzel , Christopher Behme , Stephen Thomas Davis
发明人: Adnan M.M. Mjalli , Dharma Rao Polisetti , Thomas Scott Yokum , Kalpathy Santhosh , Mustafa Guzel , Christopher Behme , Stephen Thomas Davis
IPC分类号: A61K31/5365 , C07D265/34 , A61P3/10
CPC分类号: C07D498/04 , C07D498/14
摘要: The present invention provides oxadiazoanthracene derivatives of the formula (I), wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, pharmaceutical compositions comprising oxadiazoanthracene derivatives, use of the oxadiazoanthracene derivatives for the preparation of pharmaceutical compositions, methods of use thereof for the treatment and/or prevention of disorders and diseases, such as diabetes, and intermediates useful for the preparation of oxadiazoanthracene derivatives of Formula (I).
摘要翻译: 本发明提供式(I)的恶二唑并蒽衍生物,其中A,B,C,R,R 1,R 2,R 3,R 4和R 5如本文所述,包含恶二唑并蒽衍生物的药物组合物,使用恶二唑衍生物用于制备 的药物组合物,其用于治疗和/或预防疾病和疾病的方法,例如糖尿病,以及可用于制备式(I)的恶二唑衍生物的中间体。
-
-
-
-
-
-
-
-
-